ALLO
Price
$2.17
Change
-$0.09 (-3.98%)
Updated
Feb 21 closing price
Capitalization
454.99M
4 days until earnings call
PRME
Price
$2.96
Change
-$0.17 (-5.43%)
Updated
Feb 21 closing price
Capitalization
388.24M
12 days until earnings call
Ad is loading...

ALLO vs PRME

Header iconALLO vs PRME Comparison
Open Charts ALLO vs PRMEBanner chart's image
Allogene Therapeutics
Price$2.17
Change-$0.09 (-3.98%)
Volume$4.88M
Capitalization454.99M
Prime Medicine
Price$2.96
Change-$0.17 (-5.43%)
Volume$805.56K
Capitalization388.24M
ALLO vs PRME Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALLO vs. PRME commentary
Feb 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Hold and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 22, 2025
Stock price -- (ALLO: $2.26 vs. PRME: $3.13)
Brand notoriety: ALLO and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 117% vs. PRME: 118%
Market capitalization -- ALLO: $454.99M vs. PRME: $388.24M
ALLO [@Biotechnology] is valued at $454.99M. PRME’s [@Biotechnology] market capitalization is $388.24M. The market cap for tickers in the [@Biotechnology] industry ranges from $369.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, ALLO is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 5 bullish TA indicator(s).

  • ALLO’s TA Score: 5 bullish, 4 bearish.
  • PRME’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both ALLO and PRME are a good buy in the short-term.

Price Growth

ALLO (@Biotechnology) experienced а +59.93% price change this week, while PRME (@Biotechnology) price change was +20.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.57%. For the same industry, the average monthly price growth was +3.87%, and the average quarterly price growth was +3.11%.

Reported Earning Dates

ALLO is expected to report earnings on Apr 30, 2025.

PRME is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (+4.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($455M) has a higher market cap than PRME($388M). PRME YTD gains are higher at: 7.192 vs. ALLO (5.869). PRME has higher annual earnings (EBITDA): -207.13M vs. ALLO (-256.67M). ALLO has more cash in the bank: 292M vs. PRME (176M). PRME has less debt than ALLO: PRME (41.2M) vs ALLO (85.1M). PRME has higher revenues than ALLO: PRME (800K) vs ALLO (43K).
ALLOPRMEALLO / PRME
Capitalization455M388M117%
EBITDA-256.67M-207.13M124%
Gain YTD5.8697.19282%
P/E RatioN/AN/A-
Revenue43K800K5%
Total Cash292M176M166%
Total Debt85.1M41.2M207%
FUNDAMENTALS RATINGS
ALLO vs PRME: Fundamental Ratings
ALLO
PRME
OUTLOOK RATING
1..100
839
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
4159
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (72) in the null industry is in the same range as ALLO (97) in the Biotechnology industry. This means that PRME’s stock grew similarly to ALLO’s over the last 12 months.

PRME's Profit vs Risk Rating (100) in the null industry is in the same range as ALLO (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's SMR Rating (96) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that ALLO’s stock grew similarly to PRME’s over the last 12 months.

ALLO's Price Growth Rating (41) in the Biotechnology industry is in the same range as PRME (59) in the null industry. This means that ALLO’s stock grew similarly to PRME’s over the last 12 months.

ALLO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that ALLO’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOPRME
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
76%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
74%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 12 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Ad is loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NEMCX20.18N/A
N/A
Neuberger Berman Emerg Mkts Eq C
CLTCX15.16N/A
N/A
Catalyst/Lyons Tactical Allocation C
CMGVX30.15N/A
N/A
Columbia Select Mid Cap Gro Fd I2
GLVYX89.01N/A
N/A
Invesco Global Focus Y
JATNX65.03-0.29
-0.44%
Janus Henderson Glb Tech and Innovt N

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-4.72%
CRSP - PRME
64%
Loosely correlated
-4.88%
NTLA - PRME
58%
Loosely correlated
-0.24%
BEAM - PRME
57%
Loosely correlated
-2.79%
RXRX - PRME
54%
Loosely correlated
-4.78%
ABCL - PRME
53%
Loosely correlated
-9.51%
More